ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/VEGFR2
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/VEGFR2
10
trial(s) found.
NCT07293351
Advanced
Phase 1 / Phase 2
Not yet recruiting
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (
CA266-0008
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-CTLA4 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07235293
Advanced
Phase 2
Recruiting
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer (
DSP107-003
)
VEGFR1/2/3 inhibitor
anti-PD-L1 monoclonal antibody
bifunctional CD47/4-1BB fusion protein
+ VEGFR2 inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07227402
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (
LITESPARK-033
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET/VEGFR2/AXL/MER inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
NCT07098338
Advanced
Phase 2
Recruiting
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (
LIBRA
)
Datopotamab Deruxtecan
Ramucirumab
Rilvegostomig
anti-Trop2 antibody-drug conjugate
anti-VEGFR2 monoclonal antibody
bispecific PD-1/TIGIT antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGFR2-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGFR2-targeting
therapeutic modality,bispecific antibody
+ anti-VEGFR2 monoclonal antibody
Non-small cell lung cancer
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ anti-VEGFR2 monoclonal antibody
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05691478
Advanced
Phase 2 / Phase 3
Recruiting
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (
NCI-2022-08567
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Osteosarcoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT05327686
Radonc
Phase 2
Recruiting
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (
SAMURAI
)
radiotherapy
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ VEGFR2 inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12616001187437
Advanced
Phase 2
Not recruiting
Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing. (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,first generation
ALK inhibitor,second generation
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,first generation
BCR-ABL1 inhibitor,second generation
Bortezomib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Cabozantinib
Ceritinib
Crizotinib
Dasatinib
EGFR inhibitor
EGFR inhibitor,first generation
EGFR inhibitor,type II
ERBB2 inhibitor
ERBB2 inhibitor,first generation
Erlotinib
Everolimus
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
FLT3 inhibitor
Gefitinib
HDAC inhibitor
IGF1R inhibitor
Imatinib
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,ATP-competitive
KIT inhibitor,first generation
Lapatinib
MEK inhibitor
MET inhibitor
MET inhibitor,type 1
MET inhibitor,type 2
Nilotinib
Olaparib
PARP inhibitor
PDGFRA inhibitor
PDGFR inhibitor
Palbociclib
Pazopanib
RAF inhibitor
RET inhibitor
ROS1 inhibitor
Ramucirumab
Regorafenib
SRC inhibitor
Sorafenib
Sunitinib
Trametinib
VEGFR2 inhibitor
VEGFR inhibitor
Vorinostat
YES1 inhibitor
anti-VEGFR2 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,AXL-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,ERBB2-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,FLT3-targeting
cancer therapy,HDAC-targeting
cancer therapy,IGF1R-targeting
cancer therapy,KIT-targeting
cancer therapy,MEK-targeting
cancer therapy,MET-targeting
cancer therapy,PARP-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,RAF-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,VEGFR2-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,proteasome-targeting
immuno-oncology therapy,VEGFR2-targeting
mTORC1 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
proteasome inhibitor
+ VEGFR2 inhibitor
Melanoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Not yet recruiting (1)
Enrolling by invitation (1)
Not recruiting (1)
Recruitment Country and State
NSW (8)
VIC (7)
QLD (4)
SA (4)
WA (3)
NZ (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (7)
Curative (1)
Paed (1)
Radonc (1)
Cancer Therapy Class
VEGFR2
100%
KIT
70%
RET
70%
VEGFR
70%
AXL
60%
MET
60%
PD-1/PD-L1
60%
ROS1
60%
PD-1
50%
PD-L1
30%
PDGFR
30%
CTLA4
20%
VEGFR1
20%
VEGFR3
20%
HIF2a
20%
TIGIT
20%
CDK4
20%
CDK6
20%
VEGF
20%
ERBB2
20%
PARP
20%
VEGFA
10%
MER
10%
Trop2
10%
HPK1
10%
LAG3
10%
OX40
10%
TIM3
10%
ALK
10%
BCR-ABL1
10%
CRAF
10%
EGFR
10%
FGFR1
10%
FGFR1/2/3
10%
FGFR2
10%
FGFR3
10%
FGFR4
10%
FLT3
10%
HDAC
10%
IGF1R
10%
MEK
10%
PDGFRA
10%
RAF
10%
SRC
10%
YES1
10%
mTOR
10%
mTORC1
10%
proteasome
10%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2109 - North Ryde - Macquarie University Hospital (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2145 - Westmead - The Children's Hospital at Westmead (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3011 - Footscray - Footscray Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2031 - Randwick - Sydney Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
5037 - Glandore - Ashford Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
Cancer Type
Cancer
Solid tumour
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Bone cancer
Osteosarcoma
Sarcoma
Melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy